PG · NYSE · CIK 0000080424
The Procter & Gamble Company
No equity stake in another company appears in The Procter & Gamble Company's filings. That is the sourced answer, not a hole in the research.
Share price
PG
Who owns The Procter & Gamble Company.
sized by
modelled, reported or pending
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 3,938 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
3,938 managers reported a position, together holding 1.60bn shares, or 68.8% of the company. The 40 largest are listed.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- shares_outstanding (2,324,433,060) is common stock only, as stated on the FY2026 10-K cover page as of 31 Jul 2026. It excludes the Series A and Series B ESOP Convertible Class A Preferred Stock, which are separate share classes each convertible 1-for-1 into common stock at the holder's option; those are listed under company.share_classes.
- market_cap_usd (336.00bn) and market_cap_as_of (2026-08-14, market close) are taken directly from stockanalysis.com, which also reports sharesOut of 2.32bn, consistent with the 10-K cover-page share count.
- The register mixes two different measurement dates by necessity: the 13F-derived institutional rows (Vanguard, BlackRock, State Street, Geode, Morgan Stanley) are as of 31 Mar 2026 per data/registers/PG.json, the ESOP trust row is as of 30 Jun 2026 per the FY2026 10-K, and the directors/executive-officers rows are as of 30 Jun 2025 per the most recent DEF 14A (no 2026 proxy had been filed as of 16 Aug 2026, P&G typically files it in late August ahead of an October annual meeting). Do not sum pct_of_company across rows with different as_of dates without accounting for that.
- The ESOP trust is not a member of the '27 Directors and executive officers, as a group' aggregate and does not roll up into it: it is a separate qualified-plan trust holding record title to preferred stock on behalf of the broad U.S. employee population (allocated shares belong beneficially to individual rank-and-file participants, not just officers), so it is marked with its own holder_type (esop_trust) rather than insider.
- The Glad joint venture with The Clorox Company, P&G's most notable historical minority-equity relationship, was dissolved in January 2026: Clorox purchased P&G's minority interest for $476 million (FY2026 10-K). It is not a current holding and is not included in the holdings array.
- No em dashes are used in this file per house style.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- holdings: P&G's FY2026 10-K states only, in boilerplate accounting-policy language, that the Company 'holds minor equity investments in certain companies over which we exert significant influence' (equity method) plus other equity investments carried at fair value or at cost, all lumped into the 'Other noncurrent assets' balance sheet line ($12,231 million total, which also contains lease right-of-use assets, deferred tax assets and other items). No investee company is named anywhere in the 10-K, the 2025 DEF 14A, or the 8-Ks filed since the last fiscal year end, and no equity-investment dollar figure is broken out separately from that combined line. P&G does not file a Form 13F (it is not an investment manager; none appears in its EDGAR filing history). This is treated as a sourced zero: holdings is deliberately left as an empty array rather than guessing at a named stake, because no page fetched in this task names or sizes one.
- No activist or strategic Schedule 13D was found in P&G's EDGAR filing history; the only Schedule 13D/13G-type filings on file since 2022 are routine Schedule 13G/A updates from Vanguard-family entities. Nelson Peltz's Trian Partners ran a well-known proxy contest against P&G in 2017 but does not appear in any current filing and is assumed to have exited; this was not independently re-verified with a dedicated Trian-side source in this task.
- value_usd for the ESOP trust row is left null: the 10-K's ESOP note gives share counts and a partial dollar figure for Series B ($596 million of Series B preferred outstanding at 30 Jun 2026, which is a book/liquidation-basis figure, not a market value comparable to the register's other value_usd entries which are 13F fair-market values), so no consistent market value was derived.
- Individual common-stock and Series A preferred holdings for the four non-employee directors and other officers who appear in the 2025 DEF 14A tables with small balances (Terry J. Lundgren, Patricia A. Woertz, Joseph Jimenez, Ashley McEvoy, and Series A preferred holders not listed here) were not individually itemized as separate rows; they remain inside the aggregate row's residual rather than being broken out.